Mor Moskovitz

1.9k citations

62 papers · 823 indexed · h-index 15

Impact in

Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Internal Medicine top 10%
- Venous Thromboembolism Diagnosis and Management

Papers in ⓘ

Oncology 37
- Cancer Immunotherapy and Biomarkers 11
- Lung Cancer Research Studies 11
- HER2/EGFR in Cancer Research 4
- Colorectal Cancer Treatments and Studies 4
Pulmonary and Respiratory Medicine 34
- Lung Cancer Treatments and Mutations 30
- Lung Cancer Diagnosis and Treatment 13

Co-authors: Mira Wollner (15 shared papers)Elizabeth Dudnik (17 shared papers)Jair Bar (25 shared papers)Alona Zer (25 shared papers)Tzippy Shochat (12 shared papers)Nir Peled (13 shared papers)Georgeta Fried (3 shared papers)Damien Urban (14 shared papers)
Journals: Journal of Clinical Oncology (14 papers)Journal of Thoracic Oncology (9 papers)Annals of Oncology (3 papers)Lung Cancer (2 papers)Clinical Lung Cancer (2 papers)
Partner nations: Israel United States Canada

In The Last Decade

Mor Moskovitz

59 papers receiving 795 citations

Peers

Countries citing papers authored by Mor Moskovitz

Since Specialization

Citations

This map shows the geographic impact of Mor Moskovitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mor Moskovitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mor Moskovitz more than expected).

Fields of papers citing papers by Mor Moskovitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mor Moskovitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mor Moskovitz. The network helps show where Mor Moskovitz may publish in the future.

Co-authors

The 25 scholars most cited alongside Mor Moskovitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mor Moskovitz Line = papers co-authored together Mor Moskovitz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors Journal of Thoracic Oncology ·Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, S. Keren, Noa Popovits‐Hadari, Damien Urban, Moshe Mishaeli, Alona Zer, Aaron M. Allen, Natalie Maimon Rabinovich, Ofer Rotem, Teodor Kuznetsov, Tzippy Shochat, Laila C. Roisman, Jair Bar	2018	155
2	Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome Cancers ·Gil Bar‐Sela, Idan Cohen, Salvatore Campisi‐Pinto, Gil M. Lewitus, Lanuel Oz-Ari, Ayellet Jehassi, Avivit Peer, Ilit Turgeman, Olga Vernicova, Paula Berman, Mira Wollner, Mor Moskovitz, David Meiri	2020	84
3	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data Lung Cancer ·Elizabeth Dudnik, Mor Moskovitz, Sameh Daher, Sivan Shamai, Ekaterina Hanovich, Ahuva Grubstein, Tzippy Shochat, Mira Wollner, Jair Bar, Ofer Merimsky, Alona Zer, Daniel A. Goldstein, Ariel Hammerman, Arnold Cyjon, Yelena Shechtman, Mahmood Abu-Amna, Dov Flex, Laila C. Roisman, Nir Peled	2017	80
4	ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism Clinical Lung Cancer ·Alona Zer, Mor Moskovitz, David Hwang, Anat Hershko Klement, Ludmila Fridel, Grzegorz Korpanty, Elizabeth Dudnik, Nir Peled, Tzippy Shochat, Natasha B. Leighl, Geoffrey Liu, Ronald Feld, Ronald L. Burkes, Mira Wollner, Ming‐Sound Tsao, Frances A. Shepherd	2016	72
5	Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Moiseenko, Е. А. Филиппова, İrfan Çiçin, Penelope Ann Bradbury, Nathalie Daaboul, Pascale Tomasini, Tudor–Eliade Ciuleanu, David Planchard, Mor Moskovitz, Nicolas Girard, Janet Jin, Martin Dunbar, Ellen Bolotin, Jim Looman, Christine K. Ratajczak, Shun Lü	2022	61
6	Large hiatal hernias, anemia, and linear gastric erosion: studies of etiology and medical therapy. PubMed ·Mor Moskovitz, Riley Fadden, Min Tian, D Jansma, J. S. Gavaler	1992	39
7	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data OncoImmunology ·Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem, Alona Zer, Sameh Daher, Jair Bar, (unknown)	2021	33
8	Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung Journal for ImmunoTherapy of Cancer ·Elizabeth Dudnik, Samuel A. Kareff, Mor Moskovitz, Chul Kim, Stephen V. Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar	2021	31
9	The peritoneovenous shunt: expectations and reality. PubMed ·Mor Moskovitz	1990	28
10	Trastuzumab-related cardiac events in the treatment of early breast cancer Breast Cancer Research and Treatment ·Georgeta Fried, Tslil Regev, Mor Moskovitz	2013	23
11	Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results SpringerPlus ·Georgeta Fried, Mor Moskovitz	2014	18
12	dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50% Clinical Lung Cancer ·Liran Holtzman, Mor Moskovitz, Damien Urban, Hovav Nechushtan, S. Keren, Daniel Reinhorn, Mira Wollner, Sameh Daher, Yakir Rottenberg, Yulia Rovitzky, Tzippy Shochat, Jair Bar, Elizabeth Dudnik	2021	17
13	Post-irradiation angiosarcoma of the breast: clinical presentation and outcome in a series of six cases Breast Cancer Research and Treatment ·Anton Uryvaev, Mor Moskovitz, Roxolyana Abdach-Bortnyak, Dov Hershkovitz, Georgeta Fried	2015	15
14	Oxaliplatin-Induced Pulmonary Toxicity in Gastrointestinal Malignancies: Two Case Reports and Review of the Literature SHILAP Revista de lepidopterología ·Mor Moskovitz, Mira Wollner, Nissim Haim	2015	15
15	Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer Clinical & Translational Oncology ·(unknown), Elizabeth Dudnik, Abed Agbarya, R Grinberg, Arnold Cyjon, Jair Bar, Mor Moskovitz, Nir Peled	2020	14
16	BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors Frontiers in Oncology ·Elizabeth Dudnik, Jair Bar, Assaf Moore, Teodor Gottfried, Mor Moskovitz, Julia Dudnik, Tzippy Shochat, Aaron M. Allen, Alona Zer, Ofer Rotem, Nir Peled, Damien Urban	2021	14
17	Experimentally Induced Adverse Effects of Alpha-Chymotrypsin Archives of Ophthalmology ·Christine G. O’Malley, Mor Moskovitz, B. R. Straatsma	1961	14
18	Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial. Journal of Clinical Oncology ·David Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Moiseenko, Е. А. Филиппова, İrfan Çiçin, Tudor–Eliade Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Ann Bradbury, Mor Moskovitz, Nuran Katgı, Pascale Tomasini, Alona Zer, Jim Looman, Christine K. Ratajczak, Martha Li, Summer Xia, Shun Lü	2024	8
19	Abnormal liver function tests in asymptomatic patients. PubMed ·James McKenna, Mor Moskovitz, Jafna L. Cox	1989	8
20	The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer: An Israeli prospective study Journal of Geriatric Oncology ·Shlomit Strulov Shachar, Gil Bar‐Sela, Avivit Peer, Mor Moskovitz, Avital Bareket‐Samish, Jessica Epstein, Mira Wollner, Itamar Shafran, Amit Boukal, Grant R. Williams	2022	7

About Mor Moskovitz

Mor Moskovitz is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Geriatrics and Gerontology and Biological Psychiatry, having authored 62 papers that have together received 823 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Diagnosis and Treatment (13 papers), Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Research Studies (11 papers), Cancer Genomics and Diagnostics (7 papers), HER2/EGFR in Cancer Research (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). The work is most often cited by research in Oncology (453 citations), Internal Medicine (57 citations), Pulmonary and Respiratory Medicine (406 citations), Cancer Research (89 citations) and Gastroenterology (32 citations). Mor Moskovitz has collaborated with scholars based in Israel, United States and Canada. Frequent co-authors include Mira Wollner, Elizabeth Dudnik, Jair Bar, Alona Zer, Tzippy Shochat, Nir Peled, Georgeta Fried, Damien Urban, Ofer Rotem and Hovav Nechushtan. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer and Clinical Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact